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ABSTRACT
Graft-versus-host disease (GVHD) remains a source of significant morbidity and mortality in the setting of
allogeneic stem cell transplantation. Improving outcomes in stem cell transplant recipients will require
additional therapeutic modalities for GVHD, especially for those patients who fail to respond to initial therapy
with steroids. This article provides an introduction to accompanying articles in this issue of Biology of Blood
andMarrow Transplantation concerning the current state of GVHDmanagement with an emphasis on the role
of extracorporeal photopheresis as a therapeutic modality. Topics discussed include challenges associated with
the design of clinical studies of GVHD therapies, the efficacy of and proposed mechanisms of photopheresis
in the setting of GVHD, and our emerging understanding of regulatory T cell biology as it relates to allogeneic
stem cell transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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The recognition of alloantigens by human T cells
orms the basis for several clinically signiﬁcant disease
rocesses, including graft-versus-host disease (GVHD)
rising in the setting of allogeneic stem cell transplan-
ation (SCT) [1,2]. In the setting of human SCT,
umerous interventions have been attempted to re-
uce the risk of GVHD, most of which have targeted
he number and/or function of T cells transferred
rom the donor to the recipient [3,4]. Inhibitors of
-cell activation, including cyclosporin A or tacroli-
us, are administered to nearly all SCT recipients
5,6]. Additional strategies to limit GVHD have elim-
nated T cells within the transferred graft, either by
egative depletion of CD3 T cells or the transfer of
ositively selected CD34 stem cells resulting in ef-
his work was supported by Translational Research Program Award
178-06 from the Leukemia and Lymphoma Society of America anduA109326 from the National Institutes of Health (Dr Komanduri).
B&MTective reductions of T-cell doses [7-9]. In other cases,
olyclonal or monoclonal antibodies used to purge the
llograft or administered to the recipient shortly after
raft infusion, including antithymocyte globulin (ATG)
10] or the CD52-speciﬁc agent Campath-1H [11],
ffectively result in the depletion of graft-derived T
ells. The application of one or a combination of these
trategies leads to an aggregate reduction in the risk of
VHD after SCT [6,12].
Unfortunately, the beneﬁts of decreases in mor-
idity as a result of GVHD with most current ap-
roaches are usually offset by a nonspeciﬁc reduction
n the numbers and/or function of nonalloreactive
cells, leading to an increased risk of infection and
elapse after T-cell depletion [13,14]. For many SCT
andidates, suitable matched donors are not available,
recluding the application of this potentially curative
reatment modality. Consequently, the vast majority
f transplantations performed use matched sibling or
nrelated donors because of our inability to selectively
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2educe alloreactivity in the setting of mismatched
ransplantation. Thus, improved approaches that may
llow us to deplete alloreactive T cells with relative
peciﬁcity, while sparing other T-cell populations,
ould have signiﬁcant clinical use in SCT. In this
ssue, several articles collectively review our current
nderstanding of GVHD biology [15-19]; in particu-
ar, a subset of these articles addresses the role of
xtracorporeal photopheresis (ECP) in the manage-
ent of GVHD after allogeneic SCT [15,18,19].
VHD CLINICAL TRIALS–CHALLENGES AND CAVEATS
The importance of GVHD as a source of morbid-
ty and mortality after allogeneic SCT is undisputed.
linically signiﬁcant acute GVHD may occur in 30%
r more of individuals who receive allogeneic trans-
lants from matched-related donors; the incidence is
ven higher in individuals receiving incompletely
atched allografts or those from matched unrelated
onors [20]. Although it is clear that the addition of
teroids should be the ﬁrst line of therapy for recipi-
nts of allogeneic SCT in whom prophylaxis with
yclosporine or tacrolimus has failed to prevent
VHD, there is little consensus about the optimal
herapy that should be used for steroid-refractory
cute or chronic GVHD [20]. These facts underscore
he need for ongoing clinical trials to improve the
uccess of GVHD prophylaxis, and to identify the
ptimal therapies for the initial onset of GVHD and
or the signiﬁcant subset of individuals destined to fail
rimary therapy with steroids.
In this issue, Martin and Nash [17] discuss in detail
he unique challenges that confront individuals con-
ucting clinical trials of strategies to prevent or man-
ge acute GVHD after allogeneic SCT. One impor-
ant point raised in this commentary is that survival
ifferences are likely to be greatest for those agents
hat induce dramatic reductions in the proportion of
atients developing advanced (e.g., grade III or IV)
VHD. Given the expected distribution of patients
ith early or late-stage GVHD in typical trial popu-
ations and the relative reduction of risk that may be
easonably expected with a given treatment modality,
he ability to demonstrate a signiﬁcant improvement
n survival is likely to require a large patient popula-
ion (i.e., several hundred) that may be difﬁcult to
ttain even with cooperative group enrollment [17]. In
ddition, the authors discuss other pitfalls that may
imit the success of GVHD trials, including the po-
ential for unintentional bias in open-label trials, the
nherent difﬁculty in assigning weight to GVHD-
elated manifestations that may involve multiple organ
ystems, and the challenge of determining which of
ultiple concurrent and sequential therapies is mostikely to be responsible for clinical improvement. ehey discuss these limitations in the context of an
ncreasingly more complicated health care environ-
ent in which investigators may experience pressures
rom patients, regulatory agencies, and clinical trial
ponsors.
Beyond these limitations, advances in condition-
ng regimens may also inﬂuence the pattern and inci-
ence of GVHD. It is becoming apparent that reduced-
ntensity conditioning may decrease the incidence of and
n some cases delay the onset of acute GVHD beyond
ay 100 [21]. This “delayed-onset acute GVHD” has
ed to proposals to reconsider criteria for diagnosing
hronic GVHD based on target organ involvement
nd the pattern of disease, rather than by chronology
lone. Thus, it is important to consider that tradi-
ional deﬁnitions of end points in GVHD trials may
eed to be re-evaluated as standard approaches to
ransplantation evolve, given that changes in condi-
ioning regimens may be associated with alterations in
eath caused by relapse (a competing risk for GVHD),
atterns of GVHD onset and severity, and age and
isk status of selected patients.
CP—RAYS OF LIGHT BUT ROOM FOR
NDERSTANDING
Steroid-refractory GVHD remains a daunting
hallenge after allogeneic SCT. Prior widely used
herapies, such as the infusion of polyclonal ATG,
ave often been associated with extremely high mor-
idity and mortality, often caused by infectious com-
lications. Two large studies of ATG in patients with
teroid-refractory GVHD illustrate this point all too
learly. In one, Arai et al. [22], at the Johns Hopkins
ncology Center, Baltimore, Md, studied 69 patients
ith steroid-refractory GVHD treated with ATG;
nly 4 patients survived. Khoury et al. [23] examined
8 patients retrospectively who had been treated with
TG using a variety of schedules after the failure of
teroid therapy. Although 42% of patients had im-
rovement in at least one organ system, 90% of pa-
ients died at 40 days, mainly as a result of infections
23]. Although a variety of other therapies have been
pplied in the setting of steroid-refractory GVHD,
ncluding polyclonal or monoclonal antibody prepa-
ations directed at various lymphocyte subsets, none
f these therapies has emerged as a clearly preferred
trategy. For this reason novel therapies, including
CP, have attracted interest for their potential to
imit the ongoing inﬂammatory process in GVHD
hile inducing less wholesale immune suppression.
In this issue, Couriel et al. [15] provide clinical
vidence that whatever the mechanism, ECP appears
o be associated with clinical responses in a signiﬁcant
raction of individuals who have failed to respond to
arlier lines of therapy. The authors review prior pub-
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Bished trials on the subject and also present the single-
nstitution experience with ECP at the M.D. Ander-
on Cancer Center [15]. As the authors discuss, the
ulk of the experience to date with this modality has
een with patients with chronic GVHD. Their results
uggest that subsets of patients with GVHD, espe-
ially those with chronic manifestations involving the
kin, may respond to ECP despite the failure of prior
herapies. Some caveats are worth noting. First, this
nalysis was retrospective and although a total of 71
atients were studied, the number of cases precluded
ultivariate analyses. Secondly, because the majority
f patients had chronic GVHD and there were fewer
atients with gastrointestinal disease, the suggestion
f this study that gastrointestinal responses may be
ess likely than those of other target organs (e.g., skin,
iver, and mucosal surfaces) will require conﬁrmation
n future studies. Importantly, prospective random-
zed studies may be required to clearly establish the
ole of ECP, especially in the setting of acute GVHD
herein fewer data exist.
Although ECP appears to have a justiﬁed role in
he management of GVHD, the mechanisms respon-
ible for its success in this setting are still incompletely
nderstood. In this issue, Peritt [18] discusses poten-
ial mechanisms by which ECP exerts its therapeutic
ffects. As noted in this article, ECP has been applied
linically for more than 20 years as an approved pal-
iative therapy for cutaneous T-cell lymphoma. Even
n that setting, the mechanism of action remains con-
roversial. One proposed mechanism of action of ECP
n the setting of GVHD is the induction of apoptosis
n target cells after incubation with 8-methoxypsora-
en and UVA exposure. It is postulated that antigen-
resenting cells might take up these apoptotic cells
eading to the induction of one or more possible
olerogenic functions by these antigen-presenting
ells [18]. These include production or inhibition of
ytokines that lead to a net decrease in inﬂammation,
nd secondary effects on T-cell subsets (i.e., inhibition
f activated T cells or induction of regulatory T cells)
eading to an inhibition of the effector cells likely to
e responsible for GVHD. Importantly, this review
oints out that it remains unclear which of these
echanisms, if any, are most responsible for the po-
entially beneﬁcial role of ECP in GVHD.
The article by Yamashita et al. [19] in this issue
urther adds to our current understanding of the ef-
ects of ECP on T-cell subsets that are likely to be
mportant in sustaining GVHD. Recently, advances in
uantitative immunology, including the widespread
vailability of multiparameter ﬂow cytometry and ﬂu-
rochrome-conjugated HLA-peptide tetramers, have
acilitated an improved understanding of pathways of
-cell maturation, from naive thymic emigrants to
erminally differentiated effector cells. Initially, these
tudies were focused on subsets of CD4 and CD8T s
B&MTells speciﬁc for viral pathogens (e.g., cytomegalovi-
us, Epstein-Barr virus, and HIV-1) [24,25]; more
ecently, similar techniques have allowed us to better
haracterize subsets of T cells speciﬁc for cancer an-
igens and those mediating GVHD.
In recent murine studies, GVHD was found to be
ediated by naive, but not memory, T cells [26-28].
doptive transfer of puriﬁed memory cells failed to
nduce GVHD, in contrast to the transfer of total or
uriﬁed naive T cells [26-28]. However, adult human
emory T cells, relative to those in laboratory mice
aintained in a pathogen-free environment, are likely
o be more diverse, are more likely to express activa-
ion markers [29], and may be more likely to recognize
lloantigens. We recently used a cytokine ﬂow cytom-
try assay of alloreactivity assay to determine whether
uman naive T cells (deﬁned by the coexpression of
D45RA and CD62L) and memory T cells (both
entral memory CD45RA-CD62L and effector
emory CD45RA-CD62L) cells could mediate al-
oreactivity. These experiments demonstrated that
oth naive and memory-selected human CD4T cells
ere capable of proliferation (measured by CFSE dye
ilution), produce effector cytokines, and up-regulate
D4 and secondary activation markers after alloge-
eic stimulation (Martins and Komanduri, unpub-
ished results). These data do not exclude the possi-
ility that effector memory cells (CD62L) cells
ight be less likely to mediate GVHD; however, a
rior study by Yamashita et al. [30] suggested that
evere chronic GVHD is associated with an abun-
ance of effector memory (relative to central memory)
D4 T cells.
In the study detailed here, Yamashita et al. [19]
xtend their prior work by examining the proportions
f cells expressing markers of central and effector
emory CD4 and CD8 T cells in patients with
ymptomatic chronic GVHD undergoing ECP. Im-
ortantly, they observed that patients with chronic
VHD had increases in the number of central mem-
ry (e.g., CD45RA-CCR7) CD8 T cells with con-
omitant decreases in CD4 central memory cells
19]. A subset of patients followed up longitudinally
uring ECP therapy were observed to have normal-
zation of CD4 T cells and, to a lesser extent, CD8
emory T cells. As the authors point out, this pilot
tudy could not deﬁnitively establish causality in these
ndings, nor determine patterns of change that may
redict response to GVHD therapies such as ECP. In
ddition, this study lacked other measures (e.g., char-
cterization of regulatory T-cell subsets or additional
unctional measurements) that may have conﬁrmed or
efuted prior hypotheses regarding putative mecha-
isms of ECP. However, this study does provide im-
ortant new insight into the perturbations in T-cell
aturation that are associated with GVHD; further
tudies that better characterize the subsets altered in
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4VHD and normalized after ECP should provide
nsights into effector mechanisms of GVHD. This, in
urn, should lead us to additional novel therapeutic
pproaches.
EGULATORY T CELLS AND GVHD—EARLY INSIGHTS
UT NO CLEAR ANSWERS
Recently, there has been an explosion of interest in
haracterizing the role of various subsets of regulatory
cells in human disease states, including GVHD.
he greatest concentration of studies has examined T
ells coexpressing CD4 and CD25, the interleukin-2
eceptor  chain. The CD4CD25 surface pheno-
ype demarcates a regulatory T-cell subset (Treg) that
as initially described in mice prone to autoimmu-
ity; in these animals neonatal thymectomy led to
utoimmune diseases, including a GVHD-like wast-
ng disease, which could be rescued by adding back
thymus-derived population of CD4CD25 T cells
31]. More recent studies have demonstrated that
D4CD25 T cells are capable of suppressing
VHD in murine models [32-38]. The ability to ex-
and human CD4CD25 T cells ex vivo with a
reserved ability to suppress alloreactivity has sparked
ope that adoptive therapy using expanded Treg might
e used to prevent and/or control GVHD after SCT
33,34,39-41].
In adult human beings, the circulating CD4
D25 population likely comprises both activated
nd regulatory T cells. Indeed, we found that coex-
ression of CD4 and CD25 was not sufﬁcient to
dentify donor graft Treg in human beings and that
ncreased fractions of CD4 and CD8 donor graft T
ells coexpressing CD25 were associated with more
ecipient GVHD [29]. Although overexpression of the
ranscription factor Foxp3 demarcates both murine
nd human Treg, no surface marker (or combination)
n human beings has been deﬁned that reliably dis-
riminates between activated and regulatory CD4
D25 subsets. In this issue, Hess [16] reviews cur-
ent concepts of regulatory T-cell biology germane to
VHD, derived in part from studies of cyclosporine-
nduced autologous GVHD and more recent studies
xamining CD4CD25 T cells expressing Foxp3 in
uman beings with GVHD. The complexity of this
eld is clear in this review, as are the many questions
hat must be answered before we better understand
he exact nature that regulatory T cells play in GVHD
n human beings. At this point, it is unclear which of
he many candidate surface and/or molecular markers
f regulatory T cells (e.g., CD25, CTLA-4, CD27,
ITR, Foxp3, L-selectin) best deﬁne a subpopulation
f T cells capable of preventing or controlling
VHD. Furthermore, although it was clear from the
arliest studies deﬁning murine Treg that these cellsay by thymically derived, it is unclear to what extent
ost-SCT recovery of thymic function might be nec-
ssary to regenerate and/or maintain a regulatory
-cell pool that might be essential to limit clinically
igniﬁcant GVHD, particularly in the chronic phase.
Before long, we should know whether early suc-
esses in the ﬁeld of regulatory T-cell expansion will
ranslate to clinical beneﬁt in upcoming trials de-
igned to decrease GVHD incidence through graft
ngineering [33,34,42,43]. It will also be important to
nderstand how treatments such as ECP inﬂuence the
umbers and function of Treg. We may also under-
tand how the effects of promising new conditioning
egimens (e.g., the combination of total lymphoid
rradiation with thymoglobulin) or strategies designed
o speciﬁcally deplete alloreactive T cells might inﬂu-
nce the balance of regulatory T cells versus those
ediating GVHD [44-47]. In addition to better char-
cterizing the mechanisms of candidate therapies, it
ill also be important to understand how failures of
heoretically promising agents (e.g., daclizumab)
ight be explained by unintended effects on regula-
ory T-cell subsets.
UMMARY
GVHD remains an important source of morbidity
nd mortality after allogeneic SCT. For us to optimize
utcomes for patients with HLA-matched donors and,
ore importantly, to facilitate the application of po-
entially curative SCT in patients lacking suitable do-
ors, it will be essential for us to better understand the
elative contributions of toxic conditioning, effector
nd regulatory T cells, and inﬂammatory cytokines in
he initiation and maintenance phases of GVHD. The
ollective articles in this issue highlight that although
ur conceptual understanding of this ﬁeld has signif-
cantly broadened in recent years, we still have a great
eal to learn. Importantly, we now have an increasing
rmament of tools that we may now use to character-
ze GVHD pathogenesis, and to understand how ex-
sting therapies including ECP may attenuate or sup-
ress GVHD. There is no doubt that the rapid pace of
iscovery in GVHD biology will continue to facilitate
n evolution in therapeutic strategies that should im-
rove allogeneic SCT outcomes in the not too distant
uture.
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